Detalhe da pesquisa
1.
Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression.
Proc Natl Acad Sci U S A
; 119(46): e2207201119, 2022 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36343244
2.
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Lancet Oncol
; 25(2): 184-197, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38211606
3.
Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?
Breast Cancer Res Treat
; 196(1): 97-109, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36040640
4.
Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers.
Mol Ther
; 29(7): 2350-2365, 2021 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33677091
5.
Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.
Breast Cancer Res Treat
; 185(2): 371-380, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32975708
6.
LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Mol Cancer
; 19(1): 87, 2020 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32393270
7.
The Predictive Value of Early Changes in 18 F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Oncologist
; 25(11): 927-936, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32272493
8.
Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.
Cancer
; 125(13): 2185-2193, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30892700
9.
Correction to: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
Breast Cancer Res
; 20(1): 63, 2018 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29966525
10.
MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer.
BMC Cancer
; 18(1): 74, 2018 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29329575
11.
No survival improvement of contralateral prophylactic mastectomy among women with invasive lobular carcinoma.
J Surg Oncol
; 118(6): 928-935, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30311653
12.
Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance.
Chin J Cancer Res
; 29(3): 237-252, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28729775
13.
Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
Breast Cancer Res
; 18(1): 33, 2016 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26975198
14.
A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.
BMC Cancer
; 16: 606, 2016 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27495967
15.
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.
Int J Cancer
; 136(1): 204-11, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24824628
16.
Luminal B subtype: a key factor for the worse prognosis of young breast cancer patients in China.
BMC Cancer
; 15: 201, 2015 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-25885213
17.
[Germline mutations of TP53 gene among Chinese families with high risk for breast cancer].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi
; 32(6): 761-5, 2015 Dec.
Artigo
em Zh
| MEDLINE | ID: mdl-26663043
18.
Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer.
Sci Transl Med
; 16(728): eadg7740, 2024 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38170790
19.
ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer.
Cell Res
; 34(1): 58-75, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38168642
20.
Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial.
Ther Adv Med Oncol
; 16: 17588359231225032, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38362377